$20.27
1.60[8.57%]
At close: Apr 23
$20.27
0[0.00%]
After Hours: 4:00PM EDT
Longboard Pharmaceuticals
(NASDAQ:LBPH)Longboard Pharmaceuticals Stock (NASDAQ:LBPH), Analyst Ratings, Price Targets, Predictions
Longboard Pharmaceuticals Inc has a consensus price target of $33.75, established from looking at the 29 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Cantor Fitzgerald, and HC Wainwright & Co. on April 16, 2024, April 10, 2024, and March 15, 2024. With an average price target of $60 between HC Wainwright & Co., Cantor Fitzgerald, and HC Wainwright & Co., there's an implied 196.00% upside for Longboard Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Cantor Fitzgerald
Wedbush
Citigroup
Guggenheim
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Longboard Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/16/2024 | LBPH | Buy Now | Longboard Pharmaceuticals | $20.27 | 196% | HC Wainwright & Co. | Patrick Trucchio | → $60 | Reiterates | Buy → Buy | Get Alert |
| 04/10/2024 | LBPH | Buy Now | Longboard Pharmaceuticals | $20.27 | 196% | Cantor Fitzgerald | Josh Schimmer | → $60 | Reiterates | Overweight → Overweight | Get Alert |
| 03/15/2024 | LBPH | Buy Now | Longboard Pharmaceuticals | $20.27 | 196% | HC Wainwright & Co. | Patrick Trucchio | $60 → $60 | Maintains | Buy | Get Alert |
| 03/13/2024 | LBPH | Buy Now | Longboard Pharmaceuticals | $20.27 | 196% | Cantor Fitzgerald | Josh Schimmer | → $60 | Reiterates | Overweight → Overweight | Get Alert |
| 03/13/2024 | LBPH | Buy Now | Longboard Pharmaceuticals | $20.27 | 57.87% | Wedbush | Laura Chico | → $32 | Reiterates | Outperform → Outperform | Get Alert |
| 02/16/2024 | LBPH | Buy Now | Longboard Pharmaceuticals | $20.27 | 97.34% | Citigroup | David Hoang | → $40 | Initiates | → Buy | Get Alert |
| 01/16/2024 | LBPH | Buy Now | Longboard Pharmaceuticals | $20.27 | 196% | Cantor Fitzgerald | Josh Schimmer | $55 → $60 | Maintains | Overweight | Get Alert |
| 01/08/2024 | LBPH | Buy Now | Longboard Pharmaceuticals | $20.27 | 196% | HC Wainwright & Co. | Patrick Trucchio | $25 → $60 | Maintains | Buy | Get Alert |
| 01/02/2024 | LBPH | Buy Now | Longboard Pharmaceuticals | $20.27 | 57.87% | Guggenheim | Yatin Suneja | $16 → $32 | Maintains | Buy | Get Alert |
| 01/02/2024 | LBPH | Buy Now | Longboard Pharmaceuticals | $20.27 | 171.34% | Cantor Fitzgerald | Josh Schimmer | $35 → $55 | Maintains | Overweight | Get Alert |
| 12/20/2023 | LBPH | Buy Now | Longboard Pharmaceuticals | $20.27 | 72.67% | Cantor Fitzgerald | Josh Schimmer | → $35 | Reiterates | Overweight → Overweight | Get Alert |
| 12/19/2023 | LBPH | Buy Now | Longboard Pharmaceuticals | $20.27 | 72.67% | Cantor Fitzgerald | Josh Schimmer | → $35 | Reiterates | Overweight → Overweight | Get Alert |
| 10/24/2023 | LBPH | Buy Now | Longboard Pharmaceuticals | $20.27 | 72.67% | Cantor Fitzgerald | Josh Schimmer | $16 → $35 | Assumes | → Overweight | Get Alert |
| 10/12/2023 | LBPH | Buy Now | Longboard Pharmaceuticals | $20.27 | -45.73% | Wedbush | Laura Chico | → $11 | Reiterates | Outperform → Outperform | Get Alert |
| 08/22/2023 | LBPH | Buy Now | Longboard Pharmaceuticals | $20.27 | -21.07% | Cantor Fitzgerald | Alethia Young | → $16 | Reiterates | Overweight → Overweight | Get Alert |
| 08/07/2023 | LBPH | Buy Now | Longboard Pharmaceuticals | $20.27 | 23.33% | HC Wainwright & Co. | Patrick Trucchio | → $25 | Reiterates | Buy → Buy | Get Alert |
| 07/11/2023 | LBPH | Buy Now | Longboard Pharmaceuticals | $20.27 | 23.33% | HC Wainwright & Co. | Patrick Trucchio | → $25 | Reiterates | Buy → Buy | Get Alert |
| 07/06/2023 | LBPH | Buy Now | Longboard Pharmaceuticals | $20.27 | -21.07% | Cantor Fitzgerald | Alethia Young | → $16 | Reiterates | Overweight → Overweight | Get Alert |
| 06/27/2023 | LBPH | Buy Now | Longboard Pharmaceuticals | $20.27 | -21.07% | Cantor Fitzgerald | Alethia Young | → $16 | Reiterates | Overweight → Overweight | Get Alert |
FAQ
What is the target price for Longboard Pharmaceuticals (LBPH)?
The latest price target for Longboard Pharmaceuticals (NASDAQ: LBPH) was reported by HC Wainwright & Co. on April 16, 2024. The analyst firm set a price target for $60.00 expecting LBPH to rise to within 12 months (a possible 196.00% upside). 23 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Longboard Pharmaceuticals (LBPH)?
The latest analyst rating for Longboard Pharmaceuticals (NASDAQ: LBPH) was provided by HC Wainwright & Co., and Longboard Pharmaceuticals reiterated their buy rating.
When was the last upgrade for Longboard Pharmaceuticals (LBPH)?
There is no last upgrade for Longboard Pharmaceuticals.
When was the last downgrade for Longboard Pharmaceuticals (LBPH)?
There is no last downgrade for Longboard Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Longboard Pharmaceuticals (LBPH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Longboard Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Longboard Pharmaceuticals was filed on April 16, 2024 so you should expect the next rating to be made available sometime around April 16, 2025.
Is the Analyst Rating Longboard Pharmaceuticals (LBPH) correct?
While ratings are subjective and will change, the latest Longboard Pharmaceuticals (LBPH) rating was a reiterated with a price target of $0.00 to $60.00. The current price Longboard Pharmaceuticals (LBPH) is trading at is $20.27, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.